LONG COURSE Wednesday, March 28, 2007   —  8:00 AM - 5:30 PM Convention Center 6 A/B TARGETED THERAPY OF CANCER: NEW ROLES FOR PATHOLOGISTS Click the button above to add this event to your Itinerary Planner... COURSE DIRECTORS: Marc Ladanyi, MD Memorial Sloan-Kettering Cancer Center New York, NY Allen Gown, MD PhenoPath Laboratories Seattle, WA The focus of this course will be on how targeted therapies of cancer are impacting on the practice of surgical pathology. Each talk will provide an overview of the biology behind the specific targeted therapies, the indications for their use, their clinical impact, the eligibility criteria (as defined by histology, or by detection of the target by IHC or molecular assays), specimen requirements and how testing is performed, histologic aspects of response assessment, molecular monitoring of disease, and biologic and histopathologic aspects of secondary resistance, as relevant for each cancer setting. AGENDA 8:00 Welcome & Introduction Marc Ladanyi, MD, Memorial Sloan-Kettering Cancer Center, New York, NY 8:05 Introduction & Overview of Targeted Therapies Charles Sawyers, MD, Memorial Sloan-Kettering Cancer Center, New York, NY 8:50 Leukemias James R. Downing MD, St. Jude Children’s Research Hospital, Memphis, TN 9:30 Recess, Exhibits, Poster Session V 10:45 Questions 10:50 Breast Carcinoma Allen Gown, MD, PhenoPath Laboratories, Seattle, WA 11:20 Lung Carcinoma Marc Ladanyi, MD, Memorial Sloan-Kettering Cancer Center, New York, NY 11:45 LUNCH BREAK 1:00 Questions 1:05 Colorectal Carcinoma Stanley R. Hamilton, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX 1:30 GIST and other sarcomas Cristina R. Antonescu, MD, Memorial Sloan-Kettering Cancer Center, New York, NY 2:00 Thyroid Carcinoma Yuri Nikiforov, MD PhD, University of Pittsburgh, Pittsburgh, PA 2:30 Recess, Exhibits, Poster Session VI 3:45 Questions 3:50 Prostate Carcinoma Mark Rubin, MD, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA 4:20 Brain Tumors Paul Mischel, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA 4:50 Questions and closing remarks Marc Ladanyi MD, Memorial Sloan-Kettering Cancer Center, New York, NY